This Friday, Nifty continued its northward trajectory and with the help of complete gush, managed to clock fresh record highs beyond 12,300.
"We had a good broad-based rally in the market where few marquee large-cap names joined hands with quality mid-cap counters. It’s a sign of a healthy bull run, which we believe is likely to continue."
The BSE Sensex already surpassed earlier record-high and made a fresh high of 40,392.22 last week, showing over 11 percent gains from September lows.
The S&P BSE Mid-cap index gained 4.64 percent, S&P BSE Large-cap index rose 3.49 percent and the Small-cap Index was up 2.78 percent last week.
Rajesh Agarwal of AUM Capital recommends buying RBL Bank with stop loss at Rs 552 and target of Rs 567, Indoco Remedies with stop loss at Rs 194 and target of Rs 210 and Adani Gas with stop loss at Rs 105 and target of Rs 120.
Ashwani Gujral of ashwanigujral.com has a buy on Rain Industries with a stop loss of Rs 315, target of Rs 332, a buy on United Breweries with a stop loss of Rs 1090, target of Rs 1150 and a buy on Sun Pharma Advanced Research with a stop loss of Rs 410, target of Rs 435.
Jay Thakkar of Anand Rathi Securities advises buying Greaves Cotton with a target of Rs 142.75.
Jay Thakkar of Anand Rathi Securities is of the view that one may sell RBL Bank Future with a target of Rs 506.
Moneycontrol analysed pharma stocks with a market cap of over Rs 1,000 crore. In order to find out if there are any scrips available at a reasonable valuation, we used five-year average price-to-earnings as a filter
Here are a few top buzzing stocks picked by CNBC-TV18's analysts in trade today - Neuland Labs, Titan, Cyient, Indoco Remedies, Shankara Buildpro, Ashok Leyland, TVS Motor, Tata Motors, and AB Money.
Expressing concern that drug majors are running out of cash in the US market and their generics business is shrinking, Surajit Pal of Prabhudas Lilladher said he doesn‘t expect great returns from large-cap pharma stocks.
According to Ashwani Gujral of ashwanigujral.com, one can sell Indoco Remedies and Canara Bank and buy CESC.
Mahantesh Sabarad of SBI Capital Securities has a positive view on midcap pharma including Indoco Remedies.
Ashwani Gujral of ashwanigujral.com recommends selling Dish TV and Indoco Remedies and advises buying JBF Industries.
Shahina Mukadam, Independent Market Expert advises buying Zee Media Corporation with a target of Rs 24.
Sudip Bandopadhyay of Destimoney Securities is of the view that Glenmark Pharma is the top pick and likes Ipca Labs and Indoco Remedies.
Sudip Bandopadhyay of Destimoney Securities is of the view that one may prefer midcap stocks like Mangalam Cement, Mahindra CIE and Ramkrishna Forgings.
Daljeet S Kohli, Head of Research at Indianivesh Securities feels that Indoco Remedies may touch Rs 392.
Manas Jaiswal of manasjaiswal.com is of the view that one can hold Indoco Remedies as the stock has potential to test Rs 335 in next three to four trading sessions.
Sandeep Shenoy of Anand Rathi Financial Services is of the view that one may prefer Ipca Laboratories, Unichem Laboratories and Indoco Remedies from the pharma space.
Sriram Rathi, pharma analyst at Anand Rathi is of the view that one may pick Cipla and Dr Reddys Laboratories from largecap pharma space.
Nooresh Merani of AMSEC Research advises buying Tata Global Beverage for a target price of Rs 155 and Godrej Industries for a target price of Rs 290.
Gaurav Jain of Hem Securities has recommended investing in Indoco Remedies.
Indoco Remedies can test Rs 600, says SP Tulsian, sptulsian.com.